Top High Tech Stocks To Buy For 2022

Tutor Perini (NYSE:TPC) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Tutor Perini Corporation provides diversified general contracting, construction management and design-build services to private clients and public agencies worldwide. The company operates in four segments: Civil, Building, Specialty Contractors, and Management Services. The Civil segment engages in public works construction activities and the repair, replacement, and reconstruction of infrastructure. The Building segment offers services in specialized building markets, including hospitality and gaming, transportation, healthcare, municipal offices, sports and entertainment, education, correctional facilities, biotech, pharmaceutical, industrial, and high technology. The Specialty Contractors segment provides plumbing, HVAC, electrical, mechanical, and concrete services for the industrial, commercial, hospitality and gaming, and transportation markets. The Management Services segment offers construction and design-build services to the U.S. military and government agencies, and multi-national corporations. “

Top High Tech Stocks To Buy For 2022: Chesapeake Energy Corporation(CHK)

Chesapeake Energy Corporation engages in the acquisition, exploration, and development of properties for the production of oil, natural gas, and natural gas liquids (NGL) from underground reservoirs in the United States. It operates in two segments, Exploration and Production, and Marketing, Gathering and Compression. The company holds interests in natural gas resource plays, including the Haynesville/Bossier Shales in northwestern Louisiana and East Texas; the Marcellus Shale in the northern Appalachian Basin in Pennsylvania; and the Barnett Shale in the Fort Worth Basin of north-central Texas. It also holds interests in liquids-rich resource plays, such as the Eagle Ford Shale in South Texas; the Utica Shale in Ohio and Pennsylvania; the Anadarko Basin in northwestern Oklahoma and the Texas Panhandle; and the Niobrara Shale in the Powder River Basin in Wyoming. The company owns interests in approximately 43,700 oil and natural gas wells. As of December 31, 2015, it had estimated proved reserves of 1.504 billion barrels of oil equivalent. The company also provides oil, natural gas, and NGL marketing services comprising commodity price structuring, securing and negotiating gathering, hauling, processing and transportation, contract administration, and nomination services for Chesapeake-operated wells; and marketing services for third-party producers, as well as designs, engineers, fabricates, installs, and sells natural gas compression units, accessories, and equipment used in the production, treatment, and processing of oil and natural gas. Chesapeake Energy Corporation was founded in 1989 and is headquartered in Oklahoma City, Oklahoma.

Advisors’ Opinion:

  • [By Peter Graham]

    Note that in January, Emerge Energy Services LP announced that Superior Silica Sands LLC hadsigned a new agreement with Chesapeake Energy Corporation’s(NYSE: CHK) covering frac sand supplied from Superior’s San Antonio mine in South Texas.The CEO commented:

  • [By Matthew DiLallo]

    Chesapeake Energy (NYSE:CHK) spent tens of billions of dollars gobbling up drillable land during the last decade’s shale leasing boom. A result of that buying boom is that the company tacked on a significant amount of debt to its balance sheet, which weighed it down as commodity prices plunged. That forced the company to sell off some of its drillable land to stay afloat.

  • [By Paul Ausick]

    Chesapeake Energy Corp. (NYSE: CHK) traded up about 1% at $2.93 in a 52-week range of $1.71 to $5.60.

    EOG Resources Inc. (NYSE: EOG) traded down about 1% at $94.11. The 52-week range is $82.04 to $133.53.

Top High Tech Stocks To Buy For 2022: Hill-Rom Holdings Inc(HRC)

Hill-Rom Holdings, Inc., incorporated on August 7, 1969, is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. The Company’s segments include North America, Surgical and Respiratory Care, International and Welch Allyn. The North America segment sells and rents its support and near-patient technologies and services, as well as clinical workflow solutions in the United States and Canada. The Surgical and Respiratory Care segment sells and rents its surgical and respiratory care products across the globe. The International segment sells and rents similar products as the Company’s North America segment in regions outside of the United States and Canada. The Welch Allyn segment sells medical diagnostic equipment and a portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases across the globe.

The Company’s patient care systems include various bed systems, such as Medical Surgical (MedSurg) beds, Intensive Care Unit (ICU) beds, and Bariatric patient beds, as well as mobility solutions, such as lifts and other devices used to safely move patients. Its advanced patient care systems provide patient data reporting, patient safety alarms and caregiver alerts concerning such things as bed exit, bed height, patient positioning, point of care controls, patient turn assist and upright positioning. Supporting solutions within the patient/resident room include architectural products, such as headwalls, and healthcare furniture. It rents and sells non-invasive therapeutic products and surfaces designed for the prevention and treatment of various acute and chronic medical conditions, including pulmonary, wound and bariatric conditions. Its medical equipment management and contract services provide rentals and healthcare provider asset management services for various moveable med! ical equipment (MME), such as ventilators, defibrillators, intravenous pumps and patient monitoring equipment in its North America segment. In addition, the Company sells equipment service contracts for its capital equipment, primarily in the United States.

The Company develops and markets various communications technologies and software solutions. Its communications technologies and software solutions are designed to improve patient safety and efficiency at the point of care by, among other things, enabling patient-to-staff and staff-to-staff communications, aggregating and delivering patient data, tracking staff and assets, and monitoring hand hygiene compliance. The NaviCare Platform is used to support multiple clinical solutions and applications, including nurse call, asset tracking, staff and patient locating, and hand-hygiene monitoring. This product category also includes its Welch Allyn products. It offers surgical tables, lights and pendants utilized within the operating room setting. It also offers a range of positioning devices for use in shoulder, hip, spinal and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room table. In addition, it offers operating room surgical safety and accessory products, such as scalpel and blade, light handle systems, skin markers and other disposable products. The Company offers therapeutic products that provide bronchial hygiene (airway clearance) for acute and home care patients.

The Company’s products include The Vest Airway Clearance System, which is designed to assist patients in the mobilization of retained blockages; the VitalCough System, which is a non-invasive therapy that stimulates a cough to remove secretions in patients with compromised peak cough flow, and the MetaNeb Systems, which is a triple-therapy system indicated for the mobilization of secretions, lung expansion therapy and aerosol delivery.

The Company operates through a range of channels, including sales and ren! tals of p! roducts to acute and extended care facilities across the world through both a direct sales force and distributors; sales and rentals of products directly to patients in the home, and sales into primary care facilities. Through its network of approximately 160 North American and over 50 international service centers, and approximately 1,500 service professionals, the Company provides technical support and services, and delivers its products to customers on an as-needed basis.

The Company competes with Getinge AB, Guldmann, Invacare, Joerns Healthcare, Freedom Medical, Inc., Ascom Holding, Covidien, Ltd., Exergen Corporation, GE Healthcare, Heine Optotechnik, Action Medical, DeRoyal, Draeger, MizuhoOSI, Electromed, Inc., Philips, Respirtech, Linet, Stiegelmeyer, Stryker Corporation, SIZEWise Rentals, LLC, Universal Hospital Services, Inc., Omron Healthcare, Rauland-Borg Corporation, Riester, Skytron, Steris and Swann-Morton.

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Hill-Rom (HRC)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Joseph Griffin]

    Hill-Rom (NYSE:HRC) and Globus Medical (NYSE:GMED) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Hill-Rom (HRC)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Hill-Rom (HRC)

    For more information about research offerings from Zacks Investment Research, visit

Top High Tech Stocks To Buy For 2022: Infinity Pharmaceuticals, Inc.(INFI)

Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; CONTEMPO that is in the Phase Ib/II study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; BRAVURA, which is in Phase III study to evaluate the safety and efficacy of IPI-145 plus rituximab and bendamustine; and FRESCO that is in Phase II study to evaluate the safety and efficacy of IPI-145 plus rituximab. It is also developing DYNAMO+R, which is in Phase III randomized study to evaluate IPI-145 dosed at 25 mg in combination with rituximab, a monoclonal antibody treatment; DUO that is in randomized Phase III monotherapy study evaluating IPI-145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL); and SYNCHRONY, which is in the Phase Ib study of IPI-145 in combination with obinutuzumab in CLL patients. In addition, the company is conducting a Phase Ib/II trial of IPI-145 in combination with venetoclax, a B-cell lymphoma 2 inhibitor; and developing IPI-549 that is in Phase I study for patients with various solid tumors, including melanoma and non-small cell lung cancer. The company has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI-145 in oncology; and development and license agreement with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Logan Wallace]

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI) CEO Adelene Q. Perkins sold 5,000 shares of Infinity Pharmaceuticals stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $2.82, for a total transaction of $14,100.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

  • [By Chris Lange]

    Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares made a healthy gain early on Tuesday after the firm announced a collaboration with Arcus Biosciences Inc. (NYSE: RCUS). These two companies have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types that typically show minimal response to checkpoint inhibition monotherapy.

Top High Tech Stocks To Buy For 2022: Pacific Gas & Electric Co.(PCG)

PG&E Corporation, through its subsidiary, Pacific Gas and Electric Company, transmits, delivers, and sells electricity and natural gas to residential, commercial, industrial, and agricultural customers primarily in northern and central California. The companys electricity distribution network consists of approximately 142,000 circuit miles of distribution lines, 58 transmission switching substations, and 603 distribution substations; and electricity transmission network comprises approximately 18,400 circuit miles of interconnected transmission lines and 91 electric transmission substations. Its natural gas system consists of approximately 42,800 miles of distribution pipelines, approximately 6,700 miles of backbone and local transmission pipelines, and various storage facilities. The company operates various electricity generation facilities, such as nuclear, hydroelectric, fossil fuel-fired, and photovoltaic. PG&E Corporation was founded in 1905 and is headquartered in San Francisco, California.

Advisors’ Opinion:

  • [By Shane Hupp]

    An issue of PG&E Co. (NYSE:PCG) debt rose 2.4% against its face value during trading on Tuesday. The debt issue has a 6.05% coupon and is set to mature on March 1, 2034. The debt is now trading at $93.48 and was trading at $88.63 last week. Price moves in a company’s debt in credit markets sometimes anticipate parallel moves in its share price.

  • [By Sean Williams]

    Possibly the biggest shocker of all is that David Tepper’s Appaloosa, which has a little over three dozen securities in its portfolio, was an active buyer of Northern and Central California electric and gas utility PG&E (NYSE:PCG) during the fourth quarter. Appaloosa increased its stake in the company by 62% (2.48 million shares), making it the portfolio’s fourth-largest holding.

  • [By Rich Smith]

    Shareholders of beleaguered electric utility PG&E Corporation (NYSE:PCG) got a big break today. With Citigroup upgrading the bankrupt utility stock to “buy,” PG&E shares are up 16.1% as of 12:20 p.m. EST — and climbing.

  • [By Jon C. Ogg]

    PG&E Corp. (NYSE: PCG) is still trying to recover from the potential exposure of the 2018 Camp Fire and other liabilities put the company at risk of bankruptcy. It turns out that not all bankruptcies are created equal, and some do not wipe out the entire equity value for the common shareholders. When PG&E filed for bankruptcy, it was believed at the time that there would still be value for the common shareholders.

Leave a Reply

Your email address will not be published. Required fields are marked *